Magnano L, et al. - In this study, including a training series and a validation cohort, researchers assessed life expectancy of follicular lymphoma (FL) patients based on their status at 30 months from the commencement of therapy, relative to the sex and age-matched Spanish general population (relative survival; RS). A total of 263 patients consecutively diagnosed with FL during a 10-year period who required treatment and received rituximab-containing regimens were included in the training series. From the Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO) group, they recruited an independent cohort of 693 FL patients (validation cohort). Compared to the sex- and age-matched Spanish general population, comparable survival was seen among FL patients treated with immunochemotherapy who were in complete response at 30 months.